Agomab Therapeutics (AGMB) Non-Current Assets (2024 - 2025)
Agomab Therapeutics (AGMB) posted quarterly Non-Current Assets of $37.8 million for Q4 2025, up 8.78% year-over-year from $34.7 million in Q4 2024, and up 8.78% quarter-over-quarter from $34.7 million in Q4 2024.
Agomab Therapeutics (AGMB) Non-Current Assets (2024 - 2025) Analysis & Trends
Agomab Therapeutics' Non-Current Assets history runs 2 years deep, the most recent figure standing at $37.8 million for Q4 2025.
- In Q4 2025, Non-Current Assets rose 8.78% year-over-year to $37.8 million; the TTM figure through Dec 2025 stood at $37.8 million (up 8.78% YoY), while the FY2025 annual figure was $37.8 million, up 7.4% from the prior year.
- Non-Current Assets for Q4 2025 stood at $37.8 million, up from $34.7 million in the prior quarter.
- The five-year high for Non-Current Assets was $37.8 million in Q4 2025, with the low at $34.7 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 938.60 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 6.80 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 468.65 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 18.06 Bn |
| 10 | Agomab Therapeutics | 7.07 Mn | -250.51 Mn | - | 37.71 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 37.80 Mn |
| Dec 31, 2024 | 34.74 Mn |